Research programme: liver metastases gene therapy - Custos Biotechnologie GmbHAlternative Names: Custos 1; Custos 2
Latest Information Update: 27 Apr 2007
At a glance
- Originator Custos Biotechnologie
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer metastases
Most Recent Events
- 27 Apr 2007 Discontinued - Preclinical for Cancer metastases in Germany (unspecified route)
- 12 Aug 2003 Preclinical trials in Cancer metastases in Germany (unspecified route)